rs5177 — LRP8 LRP8 3'UTR variant

3'UTR variant in LRP8 (ApoER2) that affects mRNA stability and forms part of the TACGC cardiovascular risk haplotype associated with premature myocardial infarction and coronary artery disease

See your personal result for LRP8

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

The LRP8 Haplotype Variant — A 3'UTR Risk Tag for Premature Heart Disease

LRP8, also known as ApoER2 (apolipoprotein E receptor 2), is the only member of the low-density lipoprotein receptor family expressed in platelets. It plays a central role in platelet activation, lipoprotein metabolism11 lipoprotein metabolism
LRP8 binds apolipoprotein E-containing lipoproteins and modulates their clearance from the bloodstream, and inflammatory signaling in macrophages and endothelial cells. The rs5177 variant sits in the 3' untranslated region of LRP8 and has been studied primarily as part of a haplotype block flanking the functional R952Q coding variant — together forming the TACGC haplotype22 TACGC haplotype
a five-SNP haplotype (rs7546246, rs2297660, rs3737983, R952Q/rs5174, rs5177) found exclusively in patients with familial and early-onset coronary artery disease and myocardial infarction.

The C allele at rs5177 marks one end of this risk haplotype in white populations and is notably absent from most African-ancestry populations (~1% frequency), while reaching moderate frequencies in Europeans (~32%) and high frequencies in East Asian populations (~46%), though the haplotype association with CAD has not been established in East Asian cohorts.

The Mechanism

rs5177 is a 3'UTR variant33 3'UTR variant
variants in the 3' untranslated region regulate mRNA stability, translation efficiency, and miRNA binding sites, altering how much protein is ultimately produced from the gene. Studies in psychiatric genetics examining LRP8 expression found that rs5177 is an expression quantitative trait locus (eQTL)44 expression quantitative trait locus (eQTL)
the allele at this position predicts LRP8 mRNA levels in brain and other tissues, confirming it has a real functional effect on LRP8 expression rather than being a purely neutral tag.

The cardiovascular relevance of LRP8 expression changes arises from the protein's role in platelets — LRP8 is the only LRP family member expressed on platelets55 LRP8 is the only LRP family member expressed on platelets
where it modulates HDL-mediated inhibition of platelet activation via apolipoprotein E signaling. Increased LRP8 expression has been associated with enhanced platelet reactivity and thrombotic risk. The R952Q coding variant (rs5174)66 R952Q coding variant (rs5174)
a glutamine substitution at position 952 of the LRP8 cytoplasmic tail in tight haplotype linkage with rs5177 further increases p38 MAPK activation by oxidized LDL, amplifying the platelet and inflammatory response to atherogenic lipoproteins.

Additionally, LRP8-deficient mouse models77 LRP8-deficient mouse models
animals lacking functional ApoER2 develop aortic dissection under angiotensin II infusion through dysregulated macrophage activity, suggesting LRP8 expression level in myeloid cells affects vascular wall integrity under hypertensive stress.

The Evidence

The strongest evidence comes from a series of studies by Shen, Wang, and colleagues using the GeneQuest family cohort of patients with premature coronary artery disease and MI. The 2007 discovery paper88 2007 discovery paper
Shen GQ et al., American Journal of Human Genetics 2007;81(4):780-91 identified the LRP8 locus through genome-wide linkage analysis of 428 families with premature MI, then fine-mapped to the R952Q variant. By 2014, haplotype analysis including rs517799 haplotype analysis including rs5177
Shen GQ et al., Circulation Cardiovascular Genetics 2014;7(4):514-20 showed the TACGC risk haplotype was present only in CAD/MI patients and absent from healthy controls, achieving genome-wide significance of P=7.4×10⁻⁷ for CAD and P=2.2×10⁻⁹ for MI1010 genome-wide significance of P=7.4×10⁻⁷ for CAD and P=2.2×10⁻⁹ for MI
in the GeneQuest cohort of 381 premature CAD cases vs. 560 controls, with replication in an Italian cohort of 248 familial MI patients (P=0.041). Notably, TACGC homozygotes showed earlier disease onset and higher LDL cholesterol levels1111 earlier disease onset and higher LDL cholesterol levels
compared to heterozygotes, indicating a dose-response relationship.

Complementary 2013 haplotype work1212 2013 haplotype work
Shen GQ et al., Gene 2013;521(1):78-81 identified a protective TCCGC haplotype (rs5177 G allele) with OR 0.53 for CAD (P=4.0×10⁻¹¹) and OR 0.42 for MI (P=6.5×10⁻¹²)1313 OR 0.53 for CAD (P=4.0×10⁻¹¹) and OR 0.42 for MI (P=6.5×10⁻¹²)
in the GeneQuest cohort, replicated in Italy with OR 0.71 (P=0.004), reinforcing that the G allele at rs5177 tags the protective haplotype.

Critically, a large null replication1414 large null replication
Lieb W et al., Journal of Molecular Medicine 2008;86(10):1163-70 examined LRP8 variants across four German and British cohorts totaling over 6,700 participants and found no significant association between LRP8 variants (including the rs5177 proxy rs5174) and familial or sporadic MI. This limits evidence confidence — the association appears strongest in selected familial early-onset cohorts and was absent in the South Korean replication population, suggesting population- or family-history-specific enrichment.

Practical Implications

The C allele at rs5177 tags the LRP8 risk haplotype in individuals of European ancestry with a family history of premature heart disease. The effect is most meaningful in the context of familial cardiovascular disease — where it may represent a heritable molecular marker — rather than as a general population risk predictor. The evidence supports heightened attention to platelet function, lipid management, and inflammatory markers in C allele carriers with relevant family history.

Monitoring LDL cholesterol levels is particularly important: the TACGC haplotype is associated with elevated plasma LDL and triglycerides1515 elevated plasma LDL and triglycerides
particularly in patients with early-onset CAD, suggesting lipid optimization should be a primary intervention target. Given LRP8's role in platelet activation, antiplatelet strategies may be especially relevant for affected individuals.

Interactions

The rs5177 C allele exists in tight haplotype linkage with the functional R952Q coding variant (rs5174)1616 R952Q coding variant (rs5174)
a missense change in the LRP8 cytoplasmic tail that increases p38 MAPK activation by oxidized LDL and enhances platelet reactivity. The combined TACGC haplotype (spanning rs7546246, rs2297660, rs3737983, rs5174, and rs5177) represents a coherent risk unit in white populations — the individual SNPs have limited power alone but together define a molecular diagnostic marker for familial premature CAD. When rs5177 C is present alongside rs5174 Q (risk) allele, the combined haplotype effect is stronger than either variant alone.

Genotype Interpretations

What each possible genotype means for this variant.

GG LRP8 Wild-Type Normal

Common wild-type haplotype — no elevated LRP8-related cardiovascular risk

You carry two copies of the G allele at rs5177, tagging the common wild-type LRP8 haplotype without the TACGC cardiovascular risk signature. In European populations, approximately 49% of individuals share this genotype. The G allele at this position marks the protective TCCGC haplotype, which showed roughly half the odds of coronary artery disease and myocardial infarction compared to TACGC haplotype carriers in familial CAD cohort studies.

CG TACGC Haplotype Heterozygote Intermediate

One copy of the LRP8 risk haplotype tag — moderately elevated risk in familial cardiovascular disease context

The rs5177 C allele tags the 3' end of the LRP8 TACGC risk haplotype, which also spans rs7546246, rs2297660, rs3737983, and the functional R952Q coding change (rs5174). In the GeneQuest familial CAD cohort and Italian replication, TACGC homozygotes had earlier onset of MI and higher LDL cholesterol levels than heterozygotes, establishing a gene-dose relationship. For heterozygotes, the protective TCCGC haplotype on the other chromosome may partially offset risk.

Importantly, the association is strongest in individuals with a family history of premature coronary artery disease or MI. A large null replication in over 6,700 European participants without familial enrichment found no significant association, suggesting this variant's risk is concentrated in hereditary disease families. Your C allele is most clinically meaningful if you have first-degree relatives who experienced heart attacks before age 55 (male) or 65 (female).

CC TACGC Haplotype Homozygote High Risk

Two copies of the LRP8 risk haplotype tag — highest LRP8-related risk, associated with earlier-onset CAD and elevated LDL in affected families

TACGC homozygosity at rs5177 places you in the highest-risk genotype group for this LRP8 variant. The 2014 analysis by Shen and colleagues found that TACGC homozygotes in the GeneQuest cohort experienced premature CAD and MI onset significantly earlier than heterozygotes, with higher LDL cholesterol concentrations — establishing a clear dose-dependent effect consistent with additive genetic risk.

The functional haplotype contains the R952Q coding variant (rs5174), which increases p38 MAPK activation in response to oxidized LDL in platelets, and rs5177 in the 3'UTR, which alters LRP8 mRNA stability and expression. As a homozygote, both chromosomes carry this combined risk configuration.

The context-dependence of the finding is important: the association is most established in familial, early-onset cardiovascular disease. A large European replication across >6,700 unselected participants did not confirm the signal. This suggests the CC genotype's clinical impact is highest when combined with a family history of premature heart disease. In that context, the evidence supports treating this as a significant heritable risk factor warranting proactive lipid management and cardiovascular monitoring.

Note that in East Asian populations (where C allele frequency is ~46%), the TACGC haplotype association with CAD has not been demonstrated, indicating the risk association is population-specific.